Logo-bi
Bioimpacts. 2015;5(1): 45-54. doi: 10.15171/bi.2015.12
PMID: 25901296        PMCID: PMC4401167

Review

Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients

Sepideh Zununi Vahed 1,2,3, Mohammadreza Ardalan 1,2, Nasser Samadi 1, Yadollah Omidi 3 * ORCID

Cited by CrossRef: 23

1- Neary M, Owen A. Pharmacogenetic considerations for HIV treatment in different ethnicities: an update. Expert Opinion on Drug Metabolism & Toxicology. 2017;13(11):1169 [Crossref]
2- Dash K, Mishra M. The tradeoff between the efficacy of calcineurin inhibitors: prevention of allograft rejection vs. post-transplant renal and cardiovascular complications. Critical Reviews in Toxicology. 2025;:1 [Crossref]
3- Zhang X, Xu J, Fan J, Zhang T, Li Y, Xie B, Zhang W, Lin S, Ye L, Liu Y, Jiang G. Influence of IL-18 and IL-10 Polymorphisms on Tacrolimus Elimination in Chinese Lung Transplant Patients. Disease Markers. 2017;2017:1 [Crossref]
4- Stavropoulou E, Kantartzi K, Tsigalou C, Konstantinidis T, Romanidou G, Voidarou C, Bezirtzoglou E. Focus on the Gut–Kidney Axis in Health and Disease. Front Med. 2021;7 [Crossref]
5- Genvigir F, Salgado P, Felipe C, Luo E, Alves C, Cerda A, Tedesco-Silva H, Medina-Pestana J, Oliveira N, Rodrigues A, Doi S, Hirata M, Hirata R. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients. 2016;26(10):462 [Crossref]
6- Chen Y, Han X, Sun Y, He X, Xue D. A circulating exosomal microRNA panel as a novel biomarker for monitoring post‐transplant renal graft function. J Cellular Molecular Medi. 2020;24(20):12154 [Crossref]
7- López-Ibor J, Citores M, Portoles J, Gómez-Bueno M, Sánchez-Sobrino B, Muñoz A, Cuervas-Mons V, Segovia-Cubero J. Role of TGF-β1 +869T>C polymorphism in renal dysfunction one year after heart transplantation. The Journal of Heart and Lung Transplantation. 2022;41(12):1672 [Crossref]
8- Pascual T, Apellániz-Ruiz M, Pernaut C, Cueto-Felgueroso C, Villalba P, Álvarez C, Manso L, Inglada-Pérez L, Robledo M, Rodríguez-Antona C, Ciruelos E, Nie D. Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. PLoS ONE. 2017;12(7):e0180192 [Crossref]
9- Kuznetzova A, Prazdnova E, Chistyakov V, Kutsevalova O, Batiushin M. Are Probiotics Needed in Nephrology?. Nefrologiâ (St-Peterbg). 2022;26(4):18 [Crossref]
10- Cilião H, Camargo-Godoy R, de Souza M, dos Reis M, Iastrenski L, Alvares Delfino V, Rogatto S, de Syllos Cólus I. Association of UGT2B7, UGT1A9, ABCG2, and IL23R polymorphisms with rejection risk in kidney transplant patients. Journal of Toxicology and Environmental Health, Part A. 2017;80(13-15):661 [Crossref]
11- Meor Azlan N, Koeners M, Zhang J. Regulatory control of the Na–Cl co-transporter NCC and its therapeutic potential for hypertension. Acta Pharmaceutica Sinica B. 2021;11(5):1117 [Crossref]
12- Ahmed H, Toson E, El‐mezayen H, Rashed L, Elsherbiny E. RETRACTED: Role of mesenchymal stem cells versus angiotensin converting enzyme inhibitor in kidney repair. Nephrology. 2017;22(7):531 [Crossref]
13- Asempa T, Rebellato L, Hudson S, Briley K, Maldonado A. Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients. Clinical Transplantation. 2018;32(1) [Crossref]
14- DEMİR M, MERHAMETSİZ Ö, UYAR M, SEVMİS M, AKTAS S. Outcomes of mTORi-involving minimized immunosuppression protocols in renal transplantation. 2021;4(1):71 [Crossref]
15- Zununi Vahed S, Omidi Y, Ardalan M, Samadi N. Dysregulation of urinary miR-21 and miR-200b associated with interstitial fibrosis and tubular atrophy (IFTA) in renal transplant recipients. Clinical Biochemistry. 2017;50(1-2):32 [Crossref]
16- Rajab A, Pelletier R. mTOR Inhibitor in Combination with Cyclosporine as Primary Maintenance Immunosuppression in Combined Kidney/Pancreas Transplant Recipients. Curr Transpl Rep. 2019;6(3):201 [Crossref]
17- Zununi Vahed S, Poursadegh Zonouzi A, Ghanbarian H, Ghojazadeh M, Samadi N, Omidi Y, Ardalan M. Differential expression of circulating miR-21, miR-142-3p and miR-155 in renal transplant recipients with impaired graft function. Int Urol Nephrol. 2017;49(9):1681 [Crossref]
18- Safdari R, Ferdousi R, Aziziheris K, R. Niakan-Kalhori S, Omidi Y. Computerized techniques pave the way for drug-drug interaction prediction and interpretation. Bioimpacts. 2016;6(2):71 [Crossref]
19- Genvigir F, Nishikawa A, Felipe C, Tedesco‐Silva H, Oliveira N, Salazar A, Medina‐Pestana J, Doi S, Hirata M, Hirata R. Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium–Based Treatment in Brazilian Kidney Transplant Recipients. Pharmacotherapy. 2017;37(5):535 [Crossref]
20- Xia T, Fu S, Wang Q, Wen Y, Chan S, Zhu S, Gao S, Tao X, Zhang F, Chen W. Targeted metabolomic analysis of 33 amino acids and biogenic amines in human urine by ion‐pairing HPLC‐MS/MS: Biomarkers for tacrolimus nephrotoxicity after renal transplantation. Biomedical Chromatography. 2018;32(7) [Crossref]
21- Zununi Vahed S, Poursadegh Zonouzi A, Mahmoodpoor F, Samadi N, Ardalan M, Omidi Y. Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction. Archives of Medical Research. 2017;48(1):96 [Crossref]
22- Salvadori M, Rosso G. Update on the reciprocal interference between immunosuppressive therapy and gut microbiota after kidney transplantation. World J Transplant. 2024;14(1) [Crossref]
23- Nariman‐Saleh‐Fam Z, Bastami M, Ardalan M, Sharifi S, Hosseinian Khatib S, Zununi Vahed S. Cell‐free microRNA‐148a is associated with renal allograft dysfunction: Implication for biomarker discovery. J of Cellular Biochemistry. 2019;120(4):5737 [Crossref]

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge